Patient and physician treatment preferences in relapsed/refractory follicular lymphoma: a discrete choice experiment in the United States, United Kingdom, France, Germany, Brazil, and Japan
IntroductionThe objectives of this study were to identify key treatment attributes that drive physician and patient preferences for second line (2L) and third line (3L) treatments in relapsed/refractory (R/R) follicular lymphoma (FL).MethodsA multi- country, internet-based survey was administered to...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1589722/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849427770821574656 |
|---|---|
| author | John G. Gribben Emmanuel Bachy Markqayne Ray Kathryn Krupsky Kathleen Beusterien Lewis Kopenhafer Sara Beygi Timothy Best Graeme Ball Oliver Will Madhu Palivela Anik Patel Paola Ghione |
| author_facet | John G. Gribben Emmanuel Bachy Markqayne Ray Kathryn Krupsky Kathleen Beusterien Lewis Kopenhafer Sara Beygi Timothy Best Graeme Ball Oliver Will Madhu Palivela Anik Patel Paola Ghione |
| author_sort | John G. Gribben |
| collection | DOAJ |
| description | IntroductionThe objectives of this study were to identify key treatment attributes that drive physician and patient preferences for second line (2L) and third line (3L) treatments in relapsed/refractory (R/R) follicular lymphoma (FL).MethodsA multi- country, internet-based survey was administered to patients(N=195) with R/R FL and treating physicians (N=300) from the United States, United Kingdom, France, Germany, Brazil, and Japan. The survey included two discrete choice experiments – one for 2L and one for 3L treatment options – that prompted respondents to select their preferred option between two hypothetical treatment profiles varying on seven attributes associated with treatment for R/RFL: progression-free survival (PFS), overall survival (OS), serious adverse events (AE), cytokine release syndrome (CRS) events, neurological events, fatigue, and administration. Mean preference weights and relative attribute importance were estimated in each sample, overall and by country, using hierarchical Bayesian models. Physician estimates were also stratified by practice setting.ResultsTreatment preferences for physicians and patients were most influenced by PFS. Beyond PFS, patients placed greater emphasis on the administration of medications, whereas physicians tended to focus more on five-year OS and toxicity profiles of agents. Preference for PFS above all other 2L and 3L treatment attributes was consistent for physicians, regardless of practice setting and country. However, patient treatment preferences varied by country.DiscussionThese results offer key perspectives on how physicians and patients evaluate treatment options in 2L and 3L treatment settings; this information is essential for facilitating shared decision-making in an expanding, complex treatment landscape. |
| format | Article |
| id | doaj-art-09315aa8cb4f4290aa2e7a77edefacdc |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-09315aa8cb4f4290aa2e7a77edefacdc2025-08-20T03:28:55ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-07-011510.3389/fonc.2025.15897221589722Patient and physician treatment preferences in relapsed/refractory follicular lymphoma: a discrete choice experiment in the United States, United Kingdom, France, Germany, Brazil, and JapanJohn G. Gribben0Emmanuel Bachy1Markqayne Ray2Kathryn Krupsky3Kathleen Beusterien4Lewis Kopenhafer5Sara Beygi6Timothy Best7Graeme Ball8Oliver Will9Madhu Palivela10Anik Patel11Paola Ghione12Barts Cancer Institute, Queen Mary University of London, London, United KingdomHaematology Department, Hospices Civils de Lyon, Lyon, FranceKite, A Gilead Company, Santa Monica, CA, United StatesReal World Evidence, Oracle Life Sciences, Austin, TX, United StatesReal World Evidence, Oracle Life Sciences, Austin, TX, United StatesReal World Evidence, Oracle Life Sciences, Austin, TX, United StatesKite, A Gilead Company, Santa Monica, CA, United StatesKite, A Gilead Company, Santa Monica, CA, United StatesKite, A Gilead Company, Santa Monica, CA, United StatesReal World Evidence, Oracle Life Sciences, Austin, TX, United StatesKite, A Gilead Company, Santa Monica, CA, United StatesKite, A Gilead Company, Santa Monica, CA, United StatesDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United StatesIntroductionThe objectives of this study were to identify key treatment attributes that drive physician and patient preferences for second line (2L) and third line (3L) treatments in relapsed/refractory (R/R) follicular lymphoma (FL).MethodsA multi- country, internet-based survey was administered to patients(N=195) with R/R FL and treating physicians (N=300) from the United States, United Kingdom, France, Germany, Brazil, and Japan. The survey included two discrete choice experiments – one for 2L and one for 3L treatment options – that prompted respondents to select their preferred option between two hypothetical treatment profiles varying on seven attributes associated with treatment for R/RFL: progression-free survival (PFS), overall survival (OS), serious adverse events (AE), cytokine release syndrome (CRS) events, neurological events, fatigue, and administration. Mean preference weights and relative attribute importance were estimated in each sample, overall and by country, using hierarchical Bayesian models. Physician estimates were also stratified by practice setting.ResultsTreatment preferences for physicians and patients were most influenced by PFS. Beyond PFS, patients placed greater emphasis on the administration of medications, whereas physicians tended to focus more on five-year OS and toxicity profiles of agents. Preference for PFS above all other 2L and 3L treatment attributes was consistent for physicians, regardless of practice setting and country. However, patient treatment preferences varied by country.DiscussionThese results offer key perspectives on how physicians and patients evaluate treatment options in 2L and 3L treatment settings; this information is essential for facilitating shared decision-making in an expanding, complex treatment landscape.https://www.frontiersin.org/articles/10.3389/fonc.2025.1589722/fulltreatment preferencesrelapsed/refractoryfollicular lymphomadiscrete choice experimentprogression-free survival |
| spellingShingle | John G. Gribben Emmanuel Bachy Markqayne Ray Kathryn Krupsky Kathleen Beusterien Lewis Kopenhafer Sara Beygi Timothy Best Graeme Ball Oliver Will Madhu Palivela Anik Patel Paola Ghione Patient and physician treatment preferences in relapsed/refractory follicular lymphoma: a discrete choice experiment in the United States, United Kingdom, France, Germany, Brazil, and Japan Frontiers in Oncology treatment preferences relapsed/refractory follicular lymphoma discrete choice experiment progression-free survival |
| title | Patient and physician treatment preferences in relapsed/refractory follicular lymphoma: a discrete choice experiment in the United States, United Kingdom, France, Germany, Brazil, and Japan |
| title_full | Patient and physician treatment preferences in relapsed/refractory follicular lymphoma: a discrete choice experiment in the United States, United Kingdom, France, Germany, Brazil, and Japan |
| title_fullStr | Patient and physician treatment preferences in relapsed/refractory follicular lymphoma: a discrete choice experiment in the United States, United Kingdom, France, Germany, Brazil, and Japan |
| title_full_unstemmed | Patient and physician treatment preferences in relapsed/refractory follicular lymphoma: a discrete choice experiment in the United States, United Kingdom, France, Germany, Brazil, and Japan |
| title_short | Patient and physician treatment preferences in relapsed/refractory follicular lymphoma: a discrete choice experiment in the United States, United Kingdom, France, Germany, Brazil, and Japan |
| title_sort | patient and physician treatment preferences in relapsed refractory follicular lymphoma a discrete choice experiment in the united states united kingdom france germany brazil and japan |
| topic | treatment preferences relapsed/refractory follicular lymphoma discrete choice experiment progression-free survival |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1589722/full |
| work_keys_str_mv | AT johnggribben patientandphysiciantreatmentpreferencesinrelapsedrefractoryfollicularlymphomaadiscretechoiceexperimentintheunitedstatesunitedkingdomfrancegermanybrazilandjapan AT emmanuelbachy patientandphysiciantreatmentpreferencesinrelapsedrefractoryfollicularlymphomaadiscretechoiceexperimentintheunitedstatesunitedkingdomfrancegermanybrazilandjapan AT markqayneray patientandphysiciantreatmentpreferencesinrelapsedrefractoryfollicularlymphomaadiscretechoiceexperimentintheunitedstatesunitedkingdomfrancegermanybrazilandjapan AT kathrynkrupsky patientandphysiciantreatmentpreferencesinrelapsedrefractoryfollicularlymphomaadiscretechoiceexperimentintheunitedstatesunitedkingdomfrancegermanybrazilandjapan AT kathleenbeusterien patientandphysiciantreatmentpreferencesinrelapsedrefractoryfollicularlymphomaadiscretechoiceexperimentintheunitedstatesunitedkingdomfrancegermanybrazilandjapan AT lewiskopenhafer patientandphysiciantreatmentpreferencesinrelapsedrefractoryfollicularlymphomaadiscretechoiceexperimentintheunitedstatesunitedkingdomfrancegermanybrazilandjapan AT sarabeygi patientandphysiciantreatmentpreferencesinrelapsedrefractoryfollicularlymphomaadiscretechoiceexperimentintheunitedstatesunitedkingdomfrancegermanybrazilandjapan AT timothybest patientandphysiciantreatmentpreferencesinrelapsedrefractoryfollicularlymphomaadiscretechoiceexperimentintheunitedstatesunitedkingdomfrancegermanybrazilandjapan AT graemeball patientandphysiciantreatmentpreferencesinrelapsedrefractoryfollicularlymphomaadiscretechoiceexperimentintheunitedstatesunitedkingdomfrancegermanybrazilandjapan AT oliverwill patientandphysiciantreatmentpreferencesinrelapsedrefractoryfollicularlymphomaadiscretechoiceexperimentintheunitedstatesunitedkingdomfrancegermanybrazilandjapan AT madhupalivela patientandphysiciantreatmentpreferencesinrelapsedrefractoryfollicularlymphomaadiscretechoiceexperimentintheunitedstatesunitedkingdomfrancegermanybrazilandjapan AT anikpatel patientandphysiciantreatmentpreferencesinrelapsedrefractoryfollicularlymphomaadiscretechoiceexperimentintheunitedstatesunitedkingdomfrancegermanybrazilandjapan AT paolaghione patientandphysiciantreatmentpreferencesinrelapsedrefractoryfollicularlymphomaadiscretechoiceexperimentintheunitedstatesunitedkingdomfrancegermanybrazilandjapan |